Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
Anal Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Treatment options for anal cancer are described in Table 6.
Sources: Table 6
| Stage (TNM Staging Criteria) | Treatment Options |
|---|---|
| Stage 0 | Surgery |
| Stages I, II, and III | Local resection |
| External-beam radiation therapy with chemotherapy | |
| Alternative strategies | |
| Radical resection | |
| Stage IV | Palliative surgery |
| Palliative radiation therapy | |
| Palliative chemotherapy (with or without radiation therapy) | |
| Checkpoint inhibitors |
Sources: TNM Staging Criteria · Surgery · Local resection · External-beam radiation therapy with chemotherapy · Alternative strategies · Radical resection · Palliative surgery · Palliative radiation therapy · Palliative chemotherapy (with or without radiation therapy) · Checkpoint inhibitors
The optimal approach in patients with advanced disease is still under clinical evaluation. Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[1,2] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[1-3] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[4-6] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[7] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[8]
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Stage 0 anal cancer is carcinoma in situ. Rarely diagnosed, it is a very early cancer that has not spread below the limiting membrane of the first layer of anal tissue.
Treatment options for stage 0 anal cancer include:
Sources: stage 0 anal cancer
Surgical resection is used to treat lesions of the perianal area not involving the anal sphincter. The surgical approach depends on the location of the lesion in the anal canal.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Current sphincter-sparing therapies include wide local excision for small tumors of the perianal skin or anal margin, or definitive chemoradiation therapy (fluorouracil [5-FU] and mitomycin) for cancers of the anal canal. Radical resection is reserved for patients with incomplete responses or recurrent disease.
Continued surveillance with rectal examination every 3 months for the first 2 years and endoscopy with biopsy when indicated after completion of sphincter-preserving therapy is important to monitor for recurrence.
Treatment options for stage I, stage II, and stage III anal cancer include:
Sources: stage I · stage II · stage III anal cancer
Small tumors of the perianal skin or anal margin not involving the anal sphincter may be adequately treated with local resection.[1]
Sources: 1
The standard of care for all other stage I, II, and III anal cancers in appropriate patients is chemoradiation therapy (external-beam radiation therapy [EBRT] with chemotherapy).
Sources: chemoradiation therapy
The standard of care for all other stage I, II, and III anal cancers in appropriate patients is chemoradiation therapy (external-beam radiation therapy [EBRT] with chemotherapy).
5-FU + mitomycin + radiation therapy.[2,3]
Alternative strategies such as radiation therapy alone or surgery alone may be considered, depending on the clinical context.
Radical resection is reserved for residual or recurrent cancer in the anal canal after nonoperative therapy.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Because of historically high rates of recurrence with colostomy alone, chemoradiation therapy is the preferred approach for patients with anal cancer in the absence of distant metastases.
Evidence (chemoradiation therapy):
The Anal Cancer Trial (ACT I) from the United Kingdom Co-ordinating Committee on Cancer Research demonstrated the superiority of chemoradiation with 5-FU and mitomycin over radiation therapy alone with regard to local failure and deaths from anal cancer.[2,8][Level of evidence A1]In this prospective trial, 585 patients were randomly assigned to receive 45 Gy of radiation in 20 or 25 fractions with or without 5-FU. The 5-FU was given by continuous infusion (750 mg/m2 for 5 days or 1,000 mg/m2 for 4 days) during the first and final weeks of radiation therapy, along with a single dose of mitomycin (12 mg/m2) on the first day.
Sources: 2 · 8 · Level of evidence A1
The Anal Cancer Trial (ACT I) from the United Kingdom Co-ordinating Committee on Cancer Research demonstrated the superiority of chemoradiation with 5-FU and mitomycin over radiation therapy alone with regard to local failure and deaths from anal cancer.[2,8][Level of evidence A1]In this prospective trial, 585 patients were randomly assigned to receive 45 Gy of radiation in 20 or 25 fractions with or without 5-FU. The 5-FU was given by continuous infusion (750 mg/m2 for 5 days or 1,000 mg/m2 for 4 days) during the first and final weeks of radiation therapy, along with a single dose of mitomycin (12 mg/m2) on the first day.
After a median follow-up of 13.1 years, patients who received chemoradiation therapy had a reduction in local failure (36% vs. 59%; hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.35−0.60; P < .001), risk of death from anal cancer (HR, 0.61; 95% CI, 0.49−0.76; P < .001), and relapse at 12 years (17.7% vs. 29.7%; HR, 0.70; 95% CI, 9.58−0.84; P < .001).[2][Level of evidence A1]
Sources: 2 · Level of evidence A1
There was no significant difference in overall survival (OS) in this trial (HR, 0.86; 95% CI, 0.70−1.04; P = .12).
An initial 9.1% increase in non–anal cancer deaths was observed in the first 5 years after chemoradiation therapy but was not seen at 10 years.
A European Organisation for Research and Treatment of Cancer (EORTC) trial prospectively randomly assigned 100 patients with T3 to T4 or N1 to N3 disease to receive 45 Gy of radiation with a 15-Gy or 30-Gy boost with or without 5-FU infusion (750 mg/m2 for 5 days starting on days 1 and 29) plus mitomycin (15 mg/m2 on day 1).[3][Level of evidence B1]
Sources: 3 · Level of evidence B1
A European Organisation for Research and Treatment of Cancer (EORTC) trial prospectively randomly assigned 100 patients with T3 to T4 or N1 to N3 disease to receive 45 Gy of radiation with a 15-Gy or 30-Gy boost with or without 5-FU infusion (750 mg/m2 for 5 days starting on days 1 and 29) plus mitomycin (15 mg/m2 on day 1).[3][Level of evidence B1]
Outcomes favored chemoradiation therapy with respect to 5-year colostomy-free survival rates (75% vs. 48%; P = .002) and 5-year progression-free survival (PFS) rates (60% vs. 48%; P = .05).
Subsequent trials have found capecitabine to be a reasonable replacement for 5-FU in combination with mitomycin and radiation therapy.[4,5]
While the ACT I and EORTC randomized trials established chemoradiation therapy as the preferred approach for nonmetastatic anal cancer, the substantial hematological, renal, and pulmonary toxicity of mitomycin has prompted studies of alternative regimens.
Evidence (chemoradiation therapy [alternative regimens]):
A Radiation Therapy Oncology Group (RTOG)/Eastern Cooperative Oncology Group trial of 310 patients studied chemoradiation therapy (5-FU infusion + 45 Gy of radiation) with or without mitomycin.Two large intergroup trials studied the substitution of cisplatin for mitomycin, with differing conclusions.
A Radiation Therapy Oncology Group (RTOG)/Eastern Cooperative Oncology Group trial of 310 patients studied chemoradiation therapy (5-FU infusion + 45 Gy of radiation) with or without mitomycin.Two large intergroup trials studied the substitution of cisplatin for mitomycin, with differing conclusions.
After 4-years of follow-up, patients who received mitomycin had an improved colostomy-free survival rate (71% vs. 59%; P = .014) and disease-free survival (DFS) rate (73% vs. 51%; P = .0003).[9][Level of evidence B1]
Sources: 9 · Level of evidence B1
In a phase III U.S. Intergroup trial (RTOG 9811 [NCT00003596]), patients in the cisplatin arm received two cycles of induction 5-FU and cisplatin before receiving concurrent chemoradiation therapy with 5-FU and cisplatin.[6]
In a phase III U.S. Intergroup trial (RTOG 9811 [NCT00003596]), patients in the cisplatin arm received two cycles of induction 5-FU and cisplatin before receiving concurrent chemoradiation therapy with 5-FU and cisplatin.[6]
Patients who received mitomycin had improved local control and an improved colostomy-free survival rate (90% vs. 81%; P = .02). Subsequent long-term follow-up demonstrated a borderline significant difference in the 5-year colostomy-free survival rate (71.9% vs. 65%; P = .05).[10]
Sources: 10
Long-term follow-up also demonstrated a superior 5-year DFS rate (67.8% vs. 57.8%; P = .006) and OS rate (78.3% vs. 70.7%; P = .074) for patients who received mitomycin.[11][Level of evidence B1]
Sources: 11 · Level of evidence B1
One potential explanation for the inferiority of cisplatin in this study was the delay in time to radiation therapy during induction chemotherapy.
In the prospective randomized ACT II trial, 940 patients were assigned in a 2 × 2 factorial design to receive the following: (1) either mitomycin or cisplatin during induction chemoradiation therapy and (2) either maintenance therapy with 5-FU and cisplatin in weeks 11 and 14 or no maintenance therapy.[7]
Sources: 7
In the prospective randomized ACT II trial, 940 patients were assigned in a 2 × 2 factorial design to receive the following: (1) either mitomycin or cisplatin during induction chemoradiation therapy and (2) either maintenance therapy with 5-FU and cisplatin in weeks 11 and 14 or no maintenance therapy.[7]
The complete remission rate was equivalent in patients who received mitomycin or cisplatin after a median follow-up of 5.1 years (90.5% vs. 89.6%; 95% CI, -4.9 to 3.1; P = .64). The 3-year PFS rate was also equivalent in both study groups (73% for mitomycin vs. 72% for cisplatin; HR, 0.95; 95% CI, 0.75−1.19; P = .063).[7][Level of evidence B1]
Sources: 7 · Level of evidence B1
There was also no significant effect on 3-year PFS rates among patients who received maintenance therapy or no maintenance therapy (74% vs. 73%; HR, 0.95; 95% CI, 0.75−1.21; P = .70).
This study suggests that cisplatin might reasonably substitute for mitomycin in a chemoradiation strategy.
The best time to assess a complete clinical response after chemoradiation therapy is generally after 26 weeks because delayed responses are seen.[12] Residual disease or subsequent local recurrence require further treatment.
Sources: 12
The standard salvage therapy for patients with either gross or microscopic residual disease after chemoradiation therapy has been abdominoperineal resection. Alternatively, patients may be treated with additional salvage chemoradiation therapy, chemotherapy alone, or immunotherapy.[12,13]
The optimal radiation dose in various situations has not been determined. There is insufficient evidence to determine whether the dose should be escalated for patients with T3 to T4 disease or nodal metastases, or potentially de-escalated for patients with early-stage tumors smaller than 1 cm. It is also unclear whether the chemotherapy backbone can be safely omitted for some patients with early-stage tumors, and whether such a strategy would affect the optimal dose of radiation. The roles for newer strategies such as intensity-modulated radiation therapy, proton beam therapy, and brachytherapy have yet to be conclusively determined.[14-16] Based on the National Cancer Database, higher volume radiation oncology centers report improved OS for patients with anal cancer.[17]
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Treatment options for stage IV anal cancer include:
Sources: stage IV anal cancer
Palliative surgery.
Palliative radiation therapy.
Palliative chemotherapy (with or without radiation therapy).
Palliative chemotherapy (with or without radiation therapy).
Cisplatin + infusional fluorouracil (5-FU).[1]
Sources: 1
Carboplatin + weekly paclitaxel.[2]
Sources: 2
Docetaxel + cisplatin + 5-FU.[3]
Sources: 3
Nivolumab.[4]
Sources: 4
Pembrolizumab.[5]
Sources: 5
Checkpoint inhibitors.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
In the multicenter, randomized, phase II International Advanced Anal Cancer InterAACT trial (NCT02560298), carboplatin (area under the curve 5) and weekly paclitaxel was compared with standard infusional 5-FU and bolus cisplatin in patients with advanced-stage anal cancer.[2]These promising findings have led international investigators to use carboplatin and paclitaxel as a new backbone in trials for patients with advanced-stage disease, as well as a potential partner for use with radiation therapy. Other chemotherapy regimens, such as modified docetaxel, cisplatin, and 5-FU, are under clinical evaluation.[3]
In the multicenter, randomized, phase II International Advanced Anal Cancer InterAACT trial (NCT02560298), carboplatin (area under the curve 5) and weekly paclitaxel was compared with standard infusional 5-FU and bolus cisplatin in patients with advanced-stage anal cancer.[2]These promising findings have led international investigators to use carboplatin and paclitaxel as a new backbone in trials for patients with advanced-stage disease, as well as a potential partner for use with radiation therapy. Other chemotherapy regimens, such as modified docetaxel, cisplatin, and 5-FU, are under clinical evaluation.[3]
With a median follow-up of 25.3 months, the median overall survival (OS) with carboplatin and paclitaxel was improved compared with cisplatin and 5-FU (20 months vs. 12.3 months; hazard ratio [HR], 2.0; P = .014).[Level of evidence A1]
Sources: Level of evidence A1
Serious adverse events were more common in patients treated with cisplatin plus 5-FU (62% vs. 36%; P = .016).
The checkpoint inhibitors have also shown activity for patients with metastatic disease. The phase II NCI96773 trial (NCT02314169) of single-agent nivolumab (3 mg/kg every 2 weeks) enrolled 37 patients.[4]
The checkpoint inhibitors have also shown activity for patients with metastatic disease. The phase II NCI96773 trial (NCT02314169) of single-agent nivolumab (3 mg/kg every 2 weeks) enrolled 37 patients.[4]
The overall response rate was 24%, including two complete responses.[4][Level of evidence C3]
Sources: 4 · Level of evidence C3
The phase Ib KEYNOTE-028 trial (NCT02054806) for patients with advanced tumors with programmed death ligand-1 of at least 1% enrolled a cohort of 24 patients with anal squamous cell carcinoma.[5]
Sources: KEYNOTE-028 · 5
The phase Ib KEYNOTE-028 trial (NCT02054806) for patients with advanced tumors with programmed death ligand-1 of at least 1% enrolled a cohort of 24 patients with anal squamous cell carcinoma.[5]
The overall response rate was 17%, and an additional stable disease rate was 42%.[5][Level of evidence C3]
Sources: 5 · Level of evidence C3
Although there is no clear standard of care for patients with metastatic disease, recent studies are uncovering promising new avenues for systemic treatment. Palliation of symptoms from the primary lesion is important. Patients with stage IV disease should strongly consider enrolling in clinical trials.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The tolerance of patients with HIV and anal carcinoma to standard fluorouracil and mitomycin chemoradiation therapy is not well defined.[1,2] In general, patients with HIV are treated similarly to other patients and have similar outcomes, particularly in the era of highly active antiretroviral therapy (HAART). Patients with pretreatment CD4 counts of fewer than 200 cells/μl may have increased acute and late toxic effects.[3,4] Therefore, patients with a history of AIDS-related complications may have difficulty tolerating a standard regimen, necessitating a dose adjustment or omission of mitomycin.
Source: Anal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Local recurrences and persistent disease after treatment with radiation therapy and chemotherapy or surgery as the primary treatment may be controlled by using the alternate treatment (surgical resection after radiation and vice versa).[1] Salvage chemoradiation therapy with fluorouracil and cisplatin plus a radiation boost may avoid permanent colostomy in patients with residual tumor after initial nonoperative therapy.[2] Clinical trials are exploring the use of radiation therapy with chemotherapy and radiosensitizers to improve local control.
Preliminary studies in patients with stage IV disease suggest that alternative chemotherapy regimens (such as carboplatin and paclitaxel in the InterACCT trial [NCT02560298]) or immune checkpoint inhibitors (as in NCI9673 [NCT02314169] and KEYNOTE-028 [NCT02054806]) may be beneficial in this setting.
Sources: InterACCT · NCI9673 · KEYNOTE-028
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment options for anal cancer
The following types of treatment are used:
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Local resection is a surgical procedure in which the tumor is cut from the anus along with some of the healthy tissue around it. Local resection may be used if the cancer is small and has not spread. This procedure may save the sphincter muscles so the person can still control bowel movements. Tumors that form in the lower part of the anus can often be removed with local resection.
Abdominoperineal resection is a surgical procedure in which the anus, the rectum, and part of the sigmoid colon are removed through an incision made in the abdomen. The doctor sews the end of the intestine to an opening, called a stoma, made in the surface of the abdomen so body waste can be collected in a disposable bag outside of the body. This is called a colostomy. Lymph nodes that contain cancer may also be removed during this operation. This procedure is used only for cancer that remains or comes back after treatment with radiation therapy and chemotherapy.
Sources: Abdominoperineal resection · rectum · sigmoid colon · incision · intestine · stoma · colostomy · Lymph nodes · radiation therapy
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy used to treat anal cancer:
Sources: Radiation therapy · x-rays · radiation
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: External radiation therapy
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters
Learn more about Radiation Therapy to Treat Cancer and Radiation Therapy Side Effects.
Sources: Radiation Therapy to Treat Cancer · Radiation Therapy Side Effects
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Sources: injected · systemic chemotherapy
Chemotherapy drugs used to treat anal cancer include:
capecitabine
Sources: capecitabine
cisplatin
Sources: cisplatin
fluorouracil
Sources: fluorouracil
mitomycin
Sources: mitomycin
Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.
Chemotherapy may be combined with other types of treatment, such as radiation therapy.
Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of stages I, II, and III anal cancer
Treatment of stage I, stage II, and stage III anal cancer may include:
Sources: stage I · stage II · stage III anal cancer
local resection for tumors of the skin around the outside of the anus and tumors inside the anal opening that do not involve the anal sphincter
external beam radiation therapy with chemotherapy
Sources: external beam radiation therapy · chemotherapy
radiation therapy alone
abdominoperineal resection, if cancer remains or comes back after treatment with radiation therapy and chemotherapy, or other options that may include treatment with additional chemoradiation therapy, chemotherapy alone, or immunotherapy
Sources: abdominoperineal resection · chemoradiation · immunotherapy
Those who have had treatment that saves the sphincter muscles may receive follow-up exams every 3 months for the first 2 years, including rectal exams with endoscopy and biopsy, as needed to check for recurrence.
Sources: follow-up · rectal exams · endoscopy · biopsy · recurrence
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of stage IV anal cancer
Treatment of stage IV anal cancer may include:
Sources: stage IV anal cancer
palliative surgery to relieve symptoms and improve quality of life
Sources: palliative surgery · symptoms · quality of life
palliative radiation therapy
Sources: palliative · radiation therapy
palliative chemotherapy with or without radiation therapy
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of HIV and anal cancer
In general, treatment for people who have anal cancer and HIV is similar to treatment for other people, and these patients have similar outcomes. However, this treatment can further damage the weakened immune systems of people who have HIV. Treatment for people with a history of AIDS-related complications may require lower doses of anticancer drugs and radiation therapy than doses used for patients who do not have HIV.
Sources: HIV · immune systems · AIDS · radiation therapy
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of recurrent anal cancer
Treatment of recurrent anal cancer may include:
Sources: recurrent
radiation therapy and chemotherapy, for recurrence after surgery
Sources: radiation therapy
surgery, for recurrence after radiation therapy and/or chemotherapy
Source: Anal Cancer Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Side effects of treatment
Treatment for anal cancer may cause side effects. For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Anal Cancer
ClinicalTrials.gov recordAnal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
ClinicalTrials.gov recordAnal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Anal Canal Carcinoma, Stage IIIB Anal Canal...
ClinicalTrials.gov recordSquamous Cell Carcinoma of the Anal Canal
ClinicalTrials.gov recordAnal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
ClinicalTrials.gov recordAdvanced-stage therapy
Anal Cancer
Treatment of Recurrent Anal Cancer
Treatment of Stage 0 Anal Cancer
Treatment of Stage IV Anal Cancer